First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancer

First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancer

Fluoropyrimidine+cisplatin/oxaliplatin+trastuzumab therapy is recommended for the first-line treatment of HER2-positive metastatic gastric adenocarcinoma. However, there is no comprehensive study on which platinum-based treatment should be preferred. This study aimed to compare the treatment respon...

Full description

Bibliographic Details
Main Authors: Selin Aktürk Esen, Yakup Ergun, Cihan Erol, Rukiye Arikan, Muhammed Muhiddin Er, Muhammed Mustafa Atci, Atakan Topçu, Gökhan Uçar, Baran Akagündüz, Musa Bariş Aykan, Miraç Özen, Naziyet Köse Baytemur, Melike Özçelik, Elif Şahin, Denizcan Güven, Serkan Menekşe, Naziye Ak, Fatih Teker, Engin Kut, Teoman Şakalar, Özkan Alan, Turgut Kaçan, Nazim Serdar Turhal, Saadettin Kiliçkap, Sema Türker, Mehmet Ali Nahit Şendur, Osman Köstek, Mustafa Karaağaç, Abdullah Sakin, Haci Mehmet Türk, Dilek Çağlayan, Şener Cihan, Yusuf Açikgöz, Doğan Uncu
Format: Article
Language:English
Published: Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina 2022-09-01
Series:Biomolecules & Biomedicine
Subjects:
CF
FOLFOX
gastric cancer
gastroesophageal junction cancer
trastuzumab
Online Access:https://www.bjbms.org/ojs/index.php/bjbms/article/view/7069

Internet

https://www.bjbms.org/ojs/index.php/bjbms/article/view/7069

Similar Items